Friday, January 12, 2018, London, UK: Researchers at Insilico Medicine, AgeX Therapeutics and the Biogerontology Research Foundation have published a landmark study titled "Use of deep neural network ensembles to identify embryonic-fetal transition markers: repression of COX7A1 in embryonic and cancer cells" in the journal Oncotarget.
In the study, researchers used deep learning techniques to analyze gene expression data in embryonic stem cell (ESC) lines at varying stages of development in order to characterize the gene expression profile of cells right at the boundary of the embryonic-fetal transition, when embryos become fetuses and experience a remarkable reduction in their regenerative capacity. In essence, the study's objective was to hone in on those genes responsible for the remarkable regeneratives capacities of embryos and ESCs.
This is another important step in the progress of Insilico Medicine and indicates that its suite of products is developing rapidly, with significant commercial revenues not far off" said Jim Mellon, Trustee of the Biogerontology Research Foundation, Chairman of Juvenescence Limited and a key partner of Insilico Medicine.
Mimicking the gene expression profile of cells prior to the embryonic fetal transition in adult tissues and organs is the concept underlying one of the central and most ambitious therapeutic modalities being pursued by AgeX Therapeutics, namely induced Tissue Regeneration (iTR). Therapeutic elaboration of the insights derived from this study could pave the way for in-situ tissue regeneration, and its application to ageing and age-related disease.
"induced Tissue Regeneration (iTR) is one of the most promising therapeutic modalities for enabling in-situ tissue regeneration proposed to date, and one that is likely to bring substantial healthspan-extending effects if implemented. This landmark study paves the way toward that bright future. Interestingly, in its identification of COX7A1 as one of the genes implicated in the remarkable regenerative potential of embryos and ESCs, the study also extends the purview of these findings to novel potential cancer therapies as well" said Franco Cortese, Deputy Director of the Biogerontology Research Foundation.
The authors also developed effective methods of deriving biologically-relevant information from these profiles, identifying the most interesting genes characterizing the regenerative capacity of ESCs, and performed additional experimental validation to support the findings of the study's deep learning analysis. Interestingly, one of the genes implicated in the embryonic-fetal transition that the study identified, COX7A1, is dysregulated in a diverse array of cancer types, including breast, lung, kidney, bone and muscle. As such, the results of this study could be used create novel cancer therapies as well.
"AI is quickly becoming the main driver of progress in so many fields of science, technology and human endeavor that it is easy for one to lose count. From healthcare to finance to governance, AI is galvanizing rapid paradigm shifts all around us. Insilico Medicine is rapidly establishing themselves as the leader of AI for longevity, and the combination of their deep-learning expertise with the assets for expert experimental validation and interpretation possessed by AgeX Therapeutics is a partnership that has yielded significant synergistic results in using AI to yield novel insights into the biology of aging and charting the path toward next generation healthspan-extending therapies" said Dmitry Kaminskiy, Managing Trustee of the Biogerontology Research Foundation.
Paper Reference: West M, Labat I, Sternberg H, Larocca D, Nasonkin I, Chapman K, Singh R, Makarev E, Aliper A, Kazennov A, Alekseenko A, Shuvalov N, Cheskidova E, Alekseev A, Artemov A, Putin E, Mamoshina P, Pryanichnikov P, Larocca J, Copeland K, Izumchenko E, Korzinkin M and Zhavoronkov A. Use of deep neural network ensembles to identify embryonic-fetal transition markers: repression of COX7A1 in embryonic and cancer cells, Oncotarget. 2017; in press, https:/
About the Biogerontology Research Foundation:
The Biogerontology Research Foundation is a UK non-profit research foundation and public policy center seeking to fill a gap within the research community, whereby the current scientific understanding of the ageing process is not yet being sufficiently exploited to produce effective medical interventions. The BGRF funds and conducts research which, building on the body of knowledge about how ageing happens, aims to develop biotechnological interventions to remediate the molecular and cellular deficits which accumulate with age and which underlie the ill-health of old age. Addressing ageing damage at this most fundamental level will provide an important opportunity to produce the effective, lasting treatments for the diseases and disabilities of ageing, required to improve quality of life in the elderly. The BGRF seeks to use the entire scope of modern biotechnology to attack the changes that take place in the course of ageing, and to address not just the symptoms of age-related diseases but also the mechanisms of those diseases.
About Insilico Medicine, Inc:
Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers in Baltimore with R&D resources in 6 countries. The company is widely recognized by the industry for applying next-generation artificial intelligence technology to drug discovery and aging research. For its pioneering work in the applications of Generative Adversarial Networks (GANs) and Reinforcement Learning (RL) and collaborations with the pharmaceutical companies it was selected as the Top 100 AI companies 2018 by CB Insights and Top 5 AI companies for social impact 2017 by NVIDIA. The company pursues internal drug discovery programs in cancer, dermatological, metabolic and CNS diseases, sarcopenia, fibrosis and senescence. Company website: http://www.
About AgeX Therapeutics:
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), is a biotechnology company applying technology relating to cellular immortality and regenerative biology to aging and age-related diseases. The company has three initial areas of product development: pluripotent stem cell-derived brown adipocytes (AGEX-BAT1); vascular progenitors (AGEX-VASC1); and induced Tissue Regeneration (iTR). Initial planned indications for these products are Type 2 diabetes, cardiac ischemia, and tissue regeneration respectively. For more information, please visit http://www.